As final US drug fails, SciClone focuses on breaking China
This article was originally published in Scrip
Executive Summary
Getting out of drug development is not generally a seen a value-creating move, but SciClone Pharmaceuticals turned lemons into lemonade on 2 March when it announced that it would no longer pursue approval by the US FDA of its Phase II oral mucositis drug SCV-07, enabling the company to focus solely on its China business strategy.